Cargando…

Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis

BACKGROUND: Biomarkers of disease progression in amyotrophic lateral sclerosis (ALS) could support the identification of beneficial drugs in clinical trials. We aimed to test whether soluble fragments of beta-amyloid precursor protein (sAPPα and sAPPß) correlated with clinical subtypes of ALS and we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steinacker, Petra, Fang, Lubin, Kuhle, Jens, Petzold, Axel, Tumani, Hayrettin, Ludolph, Albert C., Otto, Markus, Brettschneider, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156148/ https://www.ncbi.nlm.nih.gov/pubmed/21858182 http://dx.doi.org/10.1371/journal.pone.0023600

Ejemplares similares

Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?
por: Abdelhak, Ahmed, et al.
Publicado: (2015)

Protease-resistant SOD1 aggregates in amyotrophic lateral sclerosis demonstrated by paraffin-embedded tissue (PET) blot
por: Steinacker, Petra, et al.
Publicado: (2014)

IgG Antibodies against Measles, Rubella, and Varicella Zoster Virus Predict Conversion to Multiple Sclerosis in Clinically Isolated Syndrome
por: Brettschneider, Johannes, et al.
Publicado: (2009)

CSF Concentrations of cAMP and cGMP Are Lower in Patients with Creutzfeldt-Jakob Disease but Not Parkinson's Disease and Amyotrophic Lateral Sclerosis
por: Oeckl, Patrick, et al.
Publicado: (2012)

The Fragile X Protein Family in Amyotrophic Lateral Sclerosis
por: Mueller, Sarah, et al.
Publicado: (2023)

Non-invasive ventilation in amyotrophic lateral sclerosis
por: Dorst, Johannes, et al.
Publicado: (2019)

NAD(+) Precursors and Antioxidants for the Treatment of Amyotrophic Lateral Sclerosis
por: Obrador, Elena, et al.
Publicado: (2021)

The paradigm of amyloid precursor protein in amyotrophic lateral sclerosis: The potential role of the (682)YENPTY(687) motif
por: Matrone, Carmela
Publicado: (2023)

Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials
por: Witzel, Simon, et al.
Publicado: (2021)

Cystatin C based estimation of chronic kidney disease and amyotrophic lateral sclerosis in the ALS registry Swabia: associated risk and prognostic value
por: Nagel, Gabriele, et al.
Publicado: (2023)

Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis
por: Dorst, Johannes, et al.
Publicado: (2017)

Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis
por: Freischmidt, Axel, et al.
Publicado: (2013)

Cerebrospinal Fluid Immunoglobulin Kappa Light Chain in Clinically Isolated Syndrome and Multiple Sclerosis
por: Senel, Makbule, et al.
Publicado: (2014)

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
por: Lu, Ching-Hua, et al.
Publicado: (2015)

Saccadic intrusions in amyotrophic lateral sclerosis (ALS)
por: Becker, Wolfgang, et al.
Publicado: (2019)

Skeletal muscle in amyotrophic lateral sclerosis
por: Shefner, Jeremy M, et al.
Publicado: (2023)

Amyloid precursor protein-fragments-containing inclusions in cardiomyocytes with basophilic degeneration and its association with cerebral amyloid angiopathy and myocardial fibrosis
por: Krämer, Lara Maria, et al.
Publicado: (2018)

Eye Movement Deficits Are Consistent with a Staging Model of pTDP-43 Pathology in Amyotrophic Lateral Sclerosis
por: Gorges, Martin, et al.
Publicado: (2015)

The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS)
por: Brettschneider, Johannes, et al.
Publicado: (2010)

Amyloid-Beta Co-Pathology Is a Major Determinant of the Elevated Plasma GFAP Values in Amyotrophic Lateral Sclerosis
por: Mastrangelo, Andrea, et al.
Publicado: (2023)

Adipose Tissue Distribution Predicts Survival in Amyotrophic Lateral Sclerosis
por: Lindauer, Eva, et al.
Publicado: (2013)

DNA plasticity and damage in amyotrophic lateral sclerosis
por: Penndorf, Diane, et al.
Publicado: (2018)

Amyotrophic lateral sclerosis
por: Wijesekera, Lokesh C, et al.
Publicado: (2009)

Proteome Profiling in Murine Models of Multiple Sclerosis: Identification of Stage Specific Markers and Culprits for Tissue Damage
por: Linker, Ralf A., et al.
Publicado: (2009)

Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies
por: Huss, André, et al.
Publicado: (2020)

Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis
por: Volk, Alexander E., et al.
Publicado: (2018)

Pharyngeal electrical stimulation in amyotrophic lateral sclerosis: a pilot study
por: Herrmann, Christine, et al.
Publicado: (2022)

Diffusion Tensor Imaging in Amyotrophic Lateral Sclerosis: Machine Learning for Biomarker Development
por: Behler, Anna, et al.
Publicado: (2023)

Multiple Roles of Transforming Growth Factor Beta in Amyotrophic Lateral Sclerosis
por: Galbiati, Mariarita, et al.
Publicado: (2020)

A Role for GDNF and Soluble APP as Biomarkers of Amyotrophic Lateral Sclerosis Pathophysiology
por: Stanga, Serena, et al.
Publicado: (2018)

Multimodal in vivo staging in amyotrophic lateral sclerosis using artificial intelligence
por: Behler, Anna, et al.
Publicado: (2022)

Well-being in amyotrophic lateral sclerosis: a pilot experience sampling study
por: Real, Ruben G. L., et al.
Publicado: (2014)

Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study
por: Lu, Ching-Hua, et al.
Publicado: (2015)

Religiosity in patients with amyotrophic lateral sclerosis, a cross-country comparison
por: Ciećwierska, Katarzyna, et al.
Publicado: (2023)

Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases
por: Jesse, Sarah, et al.
Publicado: (2010)

Administration of Riluzole Oral Suspension During the Different Stages of Amyotrophic Lateral Sclerosis
por: Povedano Panades, Mónica, et al.
Publicado: (2021)

Sequential alterations in diffusion metrics as correlates of disease severity in amyotrophic lateral sclerosis
por: Müller, Hans-Peter, et al.
Publicado: (2023)

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
por: Mora, Jesus S., et al.
Publicado: (2021)

Ethical Principles in Patient-Centered Medical Care to Support Quality of Life in Amyotrophic Lateral Sclerosis
por: Lulé, Dorothée, et al.
Publicado: (2019)

Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis
por: Lu, Ching-Hua, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l0ge93h45mib59mf6lk6q6g9if